ArticleOsteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA2026
Metabolic dysfunction-associated steatotic liver disease is associated with higher bone mineral density: results from NHANES.
Article in Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
We used data from the National Health and Nutrition Examination Survey (NHANES) to investigate the association between metabolic dysfunction-associated steatotic liver disease (MASLD) and bone mineral density (BMD) among U.S. adults. Our findings indicated that participants with MASLD had higher BMD than those without MASLD.
introductionGiven the stigma associated with the term "NAFLD," experts participating in a Delphi consensus proposed renaming the condition "MASLD". Nevertheless, the association between MASLD and BMD remains unclear. This study aimed to investigate the relationship between MASLD and BMD.
methodsA cross-sectional study was conducted among 6470 participants aged 18 years or older using data from the 2005 to 2010, 2013 to 2014, and 2017 to 2018 cycles of the NHANES. MASLD was defined according to diagnostic criteria established through a Delphi consensus. Multivariable linear regression analyses were performed to evaluate the associations of MASLD with femoral neck and total femur BMD, while logistic regression analysis was used to investigate the association between MASLD and osteoporosis.
resultsAmong the 6470 participants, the mean age was 53.16 ± 17.27 years, 49.54% were male, and 23.52% met the criteria for MASLD. After multivariable adjustment, participants with MASLD had higher femoral neck BMD (β = 0.0238; 95% CI, 0.0154-0.0321) and total femur BMD (β = 0.0332; 95% CI, 0.0244-0.0419) than those without MASLD. In subgroup analyses, participants with individual cardiometabolic components of MASLD, including BMI ≥ 25 kg/m², diabetes, hypertension, and hyperlipidemia, also exhibited higher femoral BMD after multivariable adjustment. Moreover, multivariable logistic regression analysis indicated that MASLD was significantly associated with lower odds of osteoporosis.
conclusionsOur findings suggest that participants with MASLD have higher BMD compared to those without MASLD.
Indexed as
Identifiers
42859223What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.